Although decision making strategy based on clinico-histopathological criteria is well established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems characterized by distinct genetic and molecular alterations, diverse clinical courses and potential specific therapeutic vulnerabilities. Given the plethora of drugs available, the subtype-tailored treatment to RCC subtype holds the potential to improve patient outcome, shrinking treatment-related morbidity and cost. The emerging knowledge of the molecular taxonomy of RCC is evolving, whilst the antiangiogenic and immunotherapy landscape maintains and reinforces their potential. Although several prognostic factors of survival in patients with RCC have been described, no reliable predictive biomarkers of treatment individual sensitivity or resistance have been identified. In this review, we summarize the available evidence able to prompt more precise and individualized patient selection in well-designed clinical trials, covering the unmet need of medical choices in the era of next-generation anti-angiogenesis and immunotherapy.

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma / Argentiero, Antonella; Solimando, Antonio Giovanni; Krebs, Markus; Leone, Patrizia; Susca, Nicola; Brunetti, Oronzo; Racanelli, Vito; Vacca, Angelo; Silvestris, Nicola. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:5(2020), pp. 159401-159419. [10.3390/jcm9051594]

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma

Racanelli, Vito;
2020-01-01

Abstract

Although decision making strategy based on clinico-histopathological criteria is well established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems characterized by distinct genetic and molecular alterations, diverse clinical courses and potential specific therapeutic vulnerabilities. Given the plethora of drugs available, the subtype-tailored treatment to RCC subtype holds the potential to improve patient outcome, shrinking treatment-related morbidity and cost. The emerging knowledge of the molecular taxonomy of RCC is evolving, whilst the antiangiogenic and immunotherapy landscape maintains and reinforces their potential. Although several prognostic factors of survival in patients with RCC have been described, no reliable predictive biomarkers of treatment individual sensitivity or resistance have been identified. In this review, we summarize the available evidence able to prompt more precise and individualized patient selection in well-designed clinical trials, covering the unmet need of medical choices in the era of next-generation anti-angiogenesis and immunotherapy.
2020
5
Argentiero, Antonella; Solimando, Antonio Giovanni; Krebs, Markus; Leone, Patrizia; Susca, Nicola; Brunetti, Oronzo; Racanelli, Vito; Vacca, Angelo; Silvestris, Nicola
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma / Argentiero, Antonella; Solimando, Antonio Giovanni; Krebs, Markus; Leone, Patrizia; Susca, Nicola; Brunetti, Oronzo; Racanelli, Vito; Vacca, Angelo; Silvestris, Nicola. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:5(2020), pp. 159401-159419. [10.3390/jcm9051594]
File in questo prodotto:
File Dimensione Formato  
jcm-09-01594 (1).pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 743.48 kB
Formato Adobe PDF
743.48 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/386884
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 47
social impact